Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Anita D’Souza, Attaphol Pawarode et al.|Leukemia|2020Cited by 41
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Habte Yimer et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple MyelomaSagar Lonial, Shaji Kumar, Stefano Tarantolo et al.|Blood|2021Cited by 3
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Anita D’Souza, Sagar S. Patel et al.|Leukemia|2021Cited by 1
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Anita D’Souza, Sagar S. Patel et al.|Leukemia|2021Cited by 1